gms | German Medical Science

16. Deutscher Kongress für Versorgungsforschung

Deutsches Netzwerk Versorgungsforschung e. V.

4. - 6. Oktober 2017, Berlin

Artikel

Artikel empfehlen

VENTASWITCH study: Switching from Ventavis® (iloprost) V10 to V20 improves inhalation behaviour in patients with pulmonary arterial hypertension (PAH)

Meeting Abstract

Suche in Medline nach

  • Manuel Jonas Richter - Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany
  • Barbara Stollfuß - Bayer Vital GmbH, Leverkusen, Germany
  • Alexander Roitenberg - Bayer Vital GmbH, Leverkusen, Germany
  • Silke Gerlach - Bayer AG, Berlin, Germany
  • Frank Kleinjung - Bayer AG, Berlin, Germany
  • Valentin Graeff - ContraCare GmbH, Nürnberg, Germany
  • Sabine Berghaus - Bayer Vital GmbH, Leverkusen, Germany
  • Christian Müller - Bayer Vital GmbH, Leverkusen, Germany
  • Ardeschir Ghofrani - Universities of Giessen and Marburg Lung Centre, Giessen, Germany, Giessen, Germany

16. Deutscher Kongress für Versorgungsforschung (DKVF). Berlin, 04.-06.10.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocP100

doi: 10.3205/17dkvf259, urn:nbn:de:0183-17dkvf2597

Veröffentlicht: 26. September 2017

© 2017 Richter et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Ventavis is an effective therapy for patients with PAH, improving exercise capacity and symptoms. Ventavis nebuliser solution for inhalation is available as 10 µg/mL (V10) and 20 µg/mL (V20) formulations, administered using the I-Neb nebulizer. Some patients experience extended inhalation times using V10 and are at risk of incomplete inhalation and reduced inhalation frequency.

VENTASWITCH (NCT02826252) was a local, observational, case-crossover study of inhalation behaviour in 64 PAH patients enrolled in the German Ventavis patient support programme maintained on a 5 μg dose and switched from V10 to V20.

Primary outcomes were mean daily proportion of complete inhalations and inhalation frequency. Secondary outcomes were mean daily inhalation duration per session and safety. Data were collected using digital recording in the device and compared for

V10 (3 months retrospectively) and V20 formulations (3 months prospectively).

Using V20 there were significant increases in mean daily proportion of complete inhalations and inhalation frequency, and a significant decrease in mean daily inhalation duration per session (Table 1 [Tab. 1]).

Switching PAH patients from the Ventavis V10 to V20 formulation resulted in significant improvements in all primary and secondary outcomes without increasing AEs, suggesting a positive impact on inhalation behaviour which may improve adherence to therapy.